Dated: 13th February, 2014

The Deputy Manager,
Department of Corporate Services
Bombay Stock Exchange Ltd,
PJ Towers, 25<sup>th</sup> Floor
Dalal Street
Mumbai-01

Sub: Outcome of the Board meeting held on today i.e 13th February, 2014- Reg.

Ref: Scrip Code# 511509

With reference to the above subject, we would like to inform you that, the board of directors met on today and transacted the following business.

 Approved the Unaudited Financial results for the quarter and Nine months ended on 31<sup>st</sup> December, 2013

We are attaching herewith the results sheet and also the Limited Review Report from the Auditors of the company.

Thanking You

Yours Truly

1

M. Kalyan Ram Whole Time Director

FOR VIVO BIO TECHLETI

## Vivo Bio Tech Ltd.

Your Drug Discovery Partner

RT -	Medical state of		C 11	or anded on	31st December,	2013	
	Statement of Unaudited Fin	ancial Results	for the quar	er ended on	olst December,		YEAR
	equil, co		HS ENDED	ENDED			
		QUARTER ENDED				12/31/2012	3/31/2013
No.	PARTICULARS	12/31/2013	9/30/2013	12/31/2012	70. 7	Unaudited	Audited
140.		Unaudited	Unaudited	Unaudited	Ollaudited		
1	Income from Operations	453.24	357.90	363.01	1206.65	1068.01	1436.57
	a) Net Sales/ Income from Operations		0.00	0.00	2.00	3.75	3.75
	b) Other Operating Income	0.00	357.90	363.01		1071.76	1440.32
	Total Income from operations	453.24	337.90	00010			
2	Expenses						
	a. Increase/(decrease) in stock in	0.00	0.00	0.0	0.00	0.00	-2.36
	trade and WIP	36.93	203.03	0.0	0 239.95	0.00	0.00
	b. Consumption of Raw materials		0.00	0.0	0.00	0.00	373.80
	c. Purchase of traded goods	0.00	52.56	66.6	-	163.20	247.22
	d. Employees Cost	70.37	39.18		- 10	103.50	157.00
	e. Depreciation	42.10	39.10	20.0	0.00		
	f. Other Expenditure		=	251.4		10	582.38
	1.Administrative Expenditure	299.05	56.85			10	1358.04
	g Total	448.45	351.62	346.5	50 1171.07		
_	Profit/loss from Operations before other	r					
	income, finance cost and exceptions	4.79	6.28	16.	51 11.78	83.66	82.28
3	items(1-2)		21.0	-	00 59.2	0.00	72.5
4	Other income	18.00	21.0				454.0
	Profit/(loss) from Ordinary activities	22.79	27.2	8 16	51 71.0		154.8
5	before finance costs and exceptional	11.40	8.5	3 3	.75 19.9	3 77.85	77.6
6	Finance costs	11.20					
	Profit/ (loss) from Ordinary activities	a1			2.76 51.10	5.81	77.2
_	after finance costs but before exceptiona	11.39	18.75				0.0
7	111	0.00	0.0	00	0.00	0.00	
8	Profit/Loss from Ordinary Activities				2.76 51.	5.81	77.
9	(7.0)	11.39	and the second second		3.19 11.		53.
1	O Tay Eypense	3.19	2.	10	3.19		
1	Net Profit/Loss from Ordinary	0.0	0 16.	65	9.57 39.	95 -1.38	24.
1	A attivition after Tax(9-10)	8.2	0 10.	0.5			0.
	Extraordinary Items (Net of Tax expen	0.0	0	.00	0.00	-101.00	
1	2 of RsLakh)	8.2		.65	9.57 39	.95 99.62	2 24
_1	Net Profit/Loss for the Period(11-12) Paid Up Share Capital(Face Value of	0.2			0.05	935.0	935
	Paid Up Share Capital(Face variet of	935.0	935	.05 93	935	.05 933.0.	500
1	Rs.10/-each)  Reserves Excluding Revaluation						0 -111
1	Description of per Balance sheet of	0.0	00	0.00	0.00	0.00	-111
1	Earning Per Share(EPS)(Before						
	- li itams)					0.43	1
1		0.	09	0.18	0.10	7.10	
	a)Basic b)Diluted	0	09	0.18	0.10	0.43 -0.0	71

Registered Office: #608, 6<sup>th</sup> floor, Lingapur Complex, Himayath Nagar, Hyderabad – 500029, Andhra Pradesh, INDIA; Phone: +91-40-27890662-5; Fax: +91-40-27890669 Address of Preclinical Research Facility: Vivo Bio Tech Special Economic Zone, Sy. # 349/A, Pregnapur - 502311, Gajwel Mandal, Medak District, Andhra Pradesh, INDIA Email: <a href="mailto:contact@vivobio.com">contact@vivobio.com</a> Website: <a href="mailto:www.vivobio.com">www.vivobio.com</a>

## Vivo Bio Tech Ltd.

Your Drug Discovery Partner

16.ii	Earning Per Share(EPS)(After Extraordinary items)				- 10	1.07	0.26
10.11	a) Basic	0.09	0.18	0.10	0.43	1.07	0.26
_	b) Diluted	0.09	0.18	0.10	0.43	1.07	0.20
	-II- Select Information for the Qtr and year	r ended on 31/	12/2013				
	-II- Select Information for the Qu' and y						
A	Particulars of Shareholding						
1	Public Shareholding	2926437	2926437	2926437	2926437	2926437	2926437
	Number of Shares		31.30%	31.30%	31.30%	31.30%	31.30%
	Percentage of Shareholding	31.30%	31.3070	31.5076			
2	Promoters and Promoter Group Shareholding		H, 70				
	a) Pledged/Encumbered		A A	0	0	0	0.00
	:Number of Shares	0	0	0	0		
	:Percentage of Shares						
	(as a % of the total shareholding of promoter and Promoter Group)	0.00	0.00	0.00	0.00	0.00	0.00
	: Percentage of Shares						
	(as a % of the total sharecapital of the company)	0	0	0	0	0	0.00
	b) Non-Encumbered				6424083	6424083	6424083
	:Number of Shares	6424083	6424083	6424083	6424083	0424003	012100
	:Percentage of Shares				And the second		
	(as a % of the total shareholding of promoter and Promoter Group)	100%	100%	100%	100%	100%	1009
	: Percentage of Shares						
	(as a % of the total sharecapital of the company)	68.70%	68.70%	68.70%	68.70%	68.70%	68.70

Notes

The above results were reviwed by the Audit committee and approved by the Board of Directors in their meeting held on 13th February 2014 and a limited review of the same has been carried out by the statutory auditors of the company

2 Status of complaints from the investors during the quarter ended 31st December, 2013
Pending- 0 Nos Complaints Received -1 Nos., Complaints resolved - 1 Nos., Complaints lying unresolved - 0 No.


3 The company Operates in Only one Segment

Place: Hyderabad

Date: 13/02/2014

Biotoc VIVO BIO TECH LTD

M. Kalyan Ram
M. Kalyan Ram
M. Kalyan Ram



To
The Board of Directors
M/s. Vivo Bio Tech Limited
Hyderabad

Tel. (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

## Limited Review Report for the quarter ended 31st December 2013

We have reviewed the accompanying statement of unaudited financial results of M/s. Vivo Bio Tech Limited for the quarter ended 31st December 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.


For P. Murali & Co. Chartered Accountants

M.V.Joshi) Partner

No.24784

Place: Hyderabad

Date: 13<sup>th</sup> February 2014



To
The Board of Directors
M/s. Vivo Bio Tech Limited
Hyderabad

Tel. : (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

Fax : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com

info@pmurali.com

Website: www.pmurali.com

## Limited Review Report for the quarter ended 31st December 2013

We have reviewed the accompanying statement of unaudited financial results of M/s. Vivo Bio Tech Limited for the quarter ended 31st December 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co. hartered Accountants

.v.Josni) Partner

M. No.24784

Place: Hyderabad

Date: 13th February 2014